Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510170 | 0.89 | TDP1 (0.56) | ALDH1A1MAPTGFERNPSR1ATM | |
| SCHEMBL2501443 | 0.87 | IDO1 (0.54) | ALDH1A1MAPTGFERNPSR1ATM | |
| SCHEMBL2498171 | 0.85 | NOTUM (0.47) | ALDH1A1MAPTGFERNPSR1ATM | |
| SCHEMBL2502315 | 0.85 | MAP2K4 (0.49) | ALDH1A1MAPTGFERNPSR1ATM | |
| SCHEMBL10815770 | 0.82 | PDE5A (0.53) | ALDH1A1MAPTGFERNPSR1ATM | |
| SCHEMBL2492742 | 0.82 | KDM4E (0.49) | ALDH1A1MAPTGFERNPSR1ATM | |
| SCHEMBL2498676 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPTGFERALPLMAPK10 | |
| SCHEMBL2513299 | 0.80 | MEN1 (0.62) | ALDH1A1MAPTGFERKDM4EHPGD | |
| SCHEMBL14338756 | 0.78 | CYP2D6 (0.50) | ALDH1A1ATMKDM4EHSD17B10TSHR | |
| SCHEMBL14338755 | 0.78 | CYP2D6 (0.50) | ALDH1A1ATMKDM4EHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416209-A1 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | HEALTH RESEARCH INC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4247324-A1 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | Health Research, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022109469-A1 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | HEALTH RESEARCH, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109469-A1 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | HEALTH RESEARCH, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11208389-B2 | Compositions and methods for reducing cell viability | GLAX LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10793529-B2 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190330165-A1 | COMPOSITIONS AND METHODS FOR REDUCING CELL VIABILITY | GLAX LLC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190248749-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10138210-B2 | Substituted pyridazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170057931-A1 | Substituted pyridazines as prostacyclin receptor modulators | ARENA PHARMACEUTICALS, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-2370413-B1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150191454-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2015-07-09 | — | — | US | disclosed |
| US-8940891-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2370413-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010077275-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416209-A1 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | NME1, NME2, NME4 | ALDH1A1 3283/4885MAPT 2944/4885GFER 4587/4885 |
| US-10793529-B2 | Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators | PTGIR, PTGIS, TBXA2R | ALDH1A1 652/4885MAPT 3321/4885GFER 1600/4885 |
| US-20190330165-A1 | COMPOSITIONS AND METHODS FOR REDUCING CELL VIABILITY | TNF, BAX, BCL2 | ALDH1A1 1331/4885MAPT 3540/4885GFER 3280/4885 |
| US-10138210-B2 | Substituted pyridazines as prostacyclin receptor modulators | PTGIR, PTGIS, PTGER1 | ALDH1A1 683/4885MAPT 3561/4885GFER 1279/4885 |
| US-11208389-B2 | Compositions and methods for reducing cell viability | TNF, BAX, BCL2 | ALDH1A1 1331/4885MAPT 3540/4885GFER 3280/4885 |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | ALDH1A1 704/4885MAPT 3062/4885GFER 920/4885 |
| US-20170057931-A1 | Substituted pyridazines as prostacyclin receptor modulators | PTGIR, PTGIS, PTGER1 | ALDH1A1 683/4885MAPT 3561/4885GFER 1279/4885 |
| US-20190248749-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | ALDH1A1 705/4885MAPT 3054/4885GFER 912/4885 |
| US-20150191454-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | ALDH1A1 704/4885MAPT 3062/4885GFER 920/4885 |
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | PTGIR, PTGIS, TBXA2R | ALDH1A1 652/4885MAPT 3321/4885GFER 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.